TREATMENT AND DISCHARGE PATTERNS AMONG PATIENTS HOSPITALIZED WITH NON-VALVULAR ATRIAL FIBRILLATION WHO TRANSITION FROM THE INPATIENT TO OUTPATIENT SETTING
Henry J. Henk(Rutgers, The State University of New Jersey), Lien Vo(Bristol-Myers Squibb (United States)), Kevin Odell(Pfizer (United States)), Chad Patel, Mario Mendoza(Pfizer (United States)), Kenneth Tuell(Bristol-Myers Squibb (United States)), Shalabh Singhal(Integrated BioTherapeutics (United States)), Jeffrey Trocio(Pfizer (United States)), Kwanza Price(Pfizer (United States)), Jack Mardekian(Pfizer (United States))
Cited by 0
Related Papers
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
|Annals of the Rheumatic Diseases|2022|212
Risk of Major Bleeding with Concomitant Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients Receiving Long‐Term Warfarin Therapy
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2007|93